The Second Xiangya Hospital of Central South University Hospital
Recent work (1): A questionnaire investigation of hydroxychloroquine for its potential protective effect against novel coronavirus infection (COVID-19).
Recent work (2): An observational study for cardiac and pulmonary ultrasound and evaluation of treatment of severe patients with novel coronavirus pneumonia (COVID-19)
Clinical trial work (3) includes a randomized, blinded, controlled, multicenter clinical trial to evaluate the efficacy and safety of Ixekizumab combined with conventional antiviral drugs in patients with novel coronavirus pneumonia (COVID-19).
Recent work (2): An observational study for cardiac and pulmonary ultrasound and evaluation of treatment of severe patients with novel coronavirus pneumonia (COVID-19)
Clinical trial work (3) includes a randomized, blinded, controlled, multicenter clinical trial to evaluate the efficacy and safety of Ixekizumab combined with conventional antiviral drugs in patients with novel coronavirus pneumonia (COVID-19).
Technology:
COVID Labs/Universities
Industry:
COVID R&D
Headquarters:
China
Founded Date:
N/A
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership